Skip to main content
Home
  • Technologies
    • MiniPDX® - In-vivo 3D Organoid
      • MiniPDX® Methodology and Comparisons
      • MiniPDX® Application in Drug R&D and and Correlation with PDX
      • MiniPDX® for Precision Medicine
    • Patient-Derived Xenograft (PDX) Models
      • Established Patient-Derived Xenograft (PDX) Models
      • PDOX of Hematological Malignancies
      • PDOX for Brain Metastasis
    • Conditionally Reprogrammed (CR) Cells
      • A Better Alternative to Immortalized Cell Lines
      • Validation of CR Cells Heterogeneity
    • Cell Line-Derived Xenograft (CDX) Models
      • Overview
    • Immune-Oncology Platforms
      • Overview
      • Murine/Humanized Syngeneic Models
      • HuPBMC Reconstituted Models
      • HuPBMC Cancer Co-Inoculated Models
      • Macrophage Involved IO Models
      • Dentritic Cell Involved IO Models
      • Car-T In Vivo Efficacy Evaluation
      • Oncolytic Virus In Vivo Efficacy Evaluation
    • OMICS Bioinformatics Analysis
      • Overview and Bioinformatics
      • Proteomics and Functional Genomic Imaging (FGI)
      • Imaging Mass Cytometry or CyTOF Tissue Imaging
      • Revolutionary OncoVee™ K-Cell 1000 Cell Kit
  • Solutions
    • Model Systems
      • In-Vivo Models and Studies
      • In-Vitro Models and Studies
    • By Therapeutic Areas
      • Preclinical Oncology Studies
      • Immuno-Oncology (IO) Studies
      • Cell & Gene Therapy (CGT)
      • Drug Resistant Cancer Models
      • Rare Cancers and Genetic Alterations
      • Popular Expression Targets
      • Brain Metastasis
      • Hematological Malignancies (Blood Cancers)
    • By Research Phase
      • Target Identification & HIT Discovery
      • Lead Optimization and Preclinical Validation
      • Preclinical Indication Screening
      • Biomarker Identification for Companion Diagnosis
      • Clinical Testing
  • Resources
    • Downloads
    • Publications
    • Webinars
    • News & Events
  • Why LIDE
    • Mission for Precision Medicine
    • Dedicated US Leadership
    • Industry Thought Leadership
    • Highest Operational Standards
    • Scientist.com Partner
  • Model Search
  • Contact

Mobile Menu

  • Request a Quote
  • Technologies
    • MiniPDX® - In-vivo 3D Organoid
      • MiniPDX® Methodology and Comparisons
      • MiniPDX® Application in Drug R&D and and Correlation with PDX
      • MiniPDX® for Precision Medicine
    • Patient-Derived Xenograft (PDX) Models
      • Established Patient-Derived Xenograft (PDX) Models
      • PDOX of Hematological Malignancies
      • PDOX for Brain Metastasis
    • Conditionally Reprogrammed (CR) Cells
      • A Better Alternative to Immortalized Cell Lines
      • Validation of CR Cells Heterogeneity
    • Cell Line-Derived Xenograft (CDX) Models
      • Overview
    • Immune-Oncology Platforms
      • Overview
      • Murine/Humanized Syngeneic Models
      • HuPBMC Reconstituted Models
      • HuPBMC Cancer Co-Inoculated Models
      • Macrophage Involved IO Models
      • Dentritic Cell Involved IO Models
      • Car-T In Vivo Efficacy Evaluation
      • Oncolytic Virus In Vivo Efficacy Evaluatoin
    • OMICS Bioinformatics Analysis
      • Overview and Bioinformatics
      • Proteomics and Functional Genomic Imaging (FGI)
      • Imaging Mass Cytometry or CyTof Tissue Imaging
      • Revolutionary OncoVee™ K-Cell 1000 Cell Kit
  • Solutions
    • Model Systems
      • In-Vivo Models and Studies
      • In-Vitro Models and Studies
    • By Therapeutic Areas
      • Preclinical Oncology Studies
      • Immuno-Oncology (IO) Studies
      • Cell & Gene Therapy (CGT)
      • Drug Resistant Cancer Models
      • Rare Cancers and Genetic Alterations
      • Popular Expression Targets
      • Brain Metastasis
      • Hematological Malignancies (Blood Cancers)
    • By Research Phase
      • Target Identification & HIT Discovery
      • Lead Optimization and Preclinical Drug Candidate Validation
      • Preclinical Indication Screening
      • Biomarker Identification for Companion Diagnosis
      • Clinical Testing Services
  • Resources
    • Downloads
    • Publications
    • Webinars
    • News & Events
  • WHY LIDE
    • Mission for Precision Medicine
    • Dedicated US Leadership
    • Industry Thought Leadership
    • Highest Operational Standards
    • Scientist.com Partner
  • Model Search
  • Contact
Request a Quote

Cancer Type PDX/PDOX model ID CR Cell Line ID Drug Resistance Patient Drug Resistance PDX
All LD1-0041-362073 Imatinib
All LD1-1041-362519 Ibrutinib
Breast Cancer LD1-2009-361825 LD9-2009-361825 CDK4/6i
Breast Cancer LD1-2009-361973 CDK4/6i
Breast Cancer LD1-0009-362016 CDK4/6i
Breast Cancer LD1-2009-362153 CDK4/6i
Breast Cancer LD1-0009-362239 CDK4/6i\Pyrotinib
Breast Cancer LD1-2009-362263 LD9-2009-362263
Breast Cancer LD1-2009-362282 CDK4/6i
Breast Cancer LD1-2009-362310 CDK4/6i
Breast Cancer LD1-0009-362391 CDK4/6i
Lung Cancer LD1-0025-215621 Gefitinib\Icotinib
Lung Cancer LD1-0025-215625 LD9-0025-215625
Lung Cancer LD1-0025-215648 LD9-0025-215648
Lung Cancer LD1-0025-215676 LD9-0025-215676 Erlotibib Erlotibib
Lung Cancer LD1-0025-360783 Erlotibib
Lung Cancer LD1-0025-217643 Gefitinib
Lung Cancer LD1-0025-217645 Gefitinib
Lung Cancer LD1-0025-217655 Erlotinib
Lung Cancer LD1-0025-390629 AZD9291
Lung Cancer LD1-0025-390663 PD-L1
Lung Cancer LD1-0025-200662 AZD9291 Erlotinib\AZD9291
Lung Cancer LD1-0025-200694 LD9-0025-200694
Lung Cancer LD1-0025-200713 Gefitinib Erlotinib
Lung Cancer LD1-0025-200717 LD9-0025-200717 Erlotinib\AZD9291 Erlotinib\AZD9291
Lung Cancer LD1-0025-200730 Icotinib\AZD9291\Afatinib Erlotinib\AZD9291
Lung Cancer LD1-0025-200739 Icotinib Erlotinib\AZD9291
Lung Cancer LD1-0025-200756 MPDL3280A
Lung Cancer LD1-0025-360715 LD9-0025-360715
Lung Cancer LD1-0025-360764 LD9-0025-360764

Pagination

  • 1
  • 2
  • 3
  • ›› Next page
  • Last » Last page

Main navigation

  • Technologies
    • MiniPDX® - In-vivo 3D Organoid
      • MiniPDX® Methodology and Comparisons
      • MiniPDX® Application in Drug R&D and and Correlation with PDX
      • MiniPDX® for Precision Medicine
    • Patient-Derived Xenograft (PDX) Models
      • Established Patient-Derived Xenograft (PDX) Models
      • PDOX of Hematological Malignancies
      • PDOX for Brain Metastasis
    • Conditionally Reprogrammed (CR) Cells
      • A Better Alternative to Immortalized Cell Lines
      • Validation of CR Cells Heterogeneity
    • Cell Line-Derived Xenograft (CDX) Models
      • Overview
    • Immune-Oncology Platforms
      • Overview
      • Murine/Humanized Syngeneic Models
      • HuPBMC Reconstituted Models
      • HuPBMC Cancer Co-Inoculated Models
      • Macrophage Involved IO Models
      • Dentritic Cell Involved IO Models
      • Car-T In Vivo Efficacy Evaluation
      • Oncolytic Virus In Vivo Efficacy Evaluation
    • OMICS Bioinformatics Analysis
      • Overview and Bioinformatics
      • Proteomics and Functional Genomic Imaging (FGI)
      • Imaging Mass Cytometry or CyTOF Tissue Imaging
      • Revolutionary OncoVee™ K-Cell 1000 Cell Kit
  • Solutions
    • Model Systems
      • In-Vivo Models and Studies
      • In-Vitro Models and Studies
    • By Therapeutic Areas
      • Preclinical Oncology Studies
      • Immuno-Oncology (IO) Studies
      • Cell & Gene Therapy (CGT)
      • Drug Resistant Cancer Models
      • Rare Cancers and Genetic Alterations
      • Popular Expression Targets
      • Brain Metastasis
      • Hematological Malignancies (Blood Cancers)
    • By Research Phase
      • Target Identification & HIT Discovery
      • Lead Optimization and Preclinical Validation
      • Preclinical Indication Screening
      • Biomarker Identification for Companion Diagnosis
      • Clinical Testing
  • Resources
    • Downloads
    • Publications
    • Webinars
    • News & Events
  • Why LIDE
    • Mission for Precision Medicine
    • Dedicated US Leadership
    • Industry Thought Leadership
    • Highest Operational Standards
    • Scientist.com Partner
  • Model Search
  • Contact
Ask an Expert

Ask Our Experts

Ask our Experts

Sign Up for Updates

Sign Up for Updates

The subscriber's email address.

By signing up, you agree to LIDE's Terms and Privacy Policy. Unsubscribe at any time.

Logo Footer
Certification - aaalac
Lide

LIDE is a translational medicine service provider (CRO) with 11 years of delivering innovations in oncology translational research. Our bedside-to-bench platform increases likelihood of success in drug R&D. 

Call us at +1 (878) 999-8415

Featured Services Links

Featured Services

Functional Diagnosis
I/O Platform
PDX
MiniPDX
CR
K cell & FGI

Corporate Links

Corporate

Mission and History
Dedicated US Leadership
Contact Us
Site Map
Terms of Use
Privacy Policy

Subsidiaries

Subsidiaries

LIWEN Logo

Footer Copyright

© 2021-2022 LIDE Shanghai Biotech, Ltd   沪ICP备15051385号-3